Achieve Life Sciences, Inc. (ACHV) Balance Sheet

The balance sheet has deteriorated sharply, with total liabilities exceeding total assets in 2026Q2, pushing equity negative. This shift is driven by persistent operating losses and a reliance on dilutive equity financing, as evidenced by the jump in cash from $28.1M to $48.0M in 2026Q2, likely from a capital raise. The negative equity signals that the company is burning through its capital base faster than it can generate returns, a common but precarious state for pre-revenue biotechs.

The debt-to-equity ratio, though volatile, has trended upward, reaching 1.40 in 2026Q1 before equity turned negative. This suggests that the company is increasingly using debt to fund operations, likely due to limited access to equity markets at favorable terms. The absolute debt level remains modest, but with no revenue and a constrained cash position, the leverage adds financial risk, especially if the CRL delay extends the pre-commercial period.

The asset mix is dominated by cash and a $1.0M goodwill figure, with virtually no fixed assets, reflecting a typical clinical-stage biotech that outsources manufacturing and R&D. The negligible PPE suggests minimal capital intensity, but the goodwill, though small, may be at risk of impairment if the CRL leads to a reassessment of the pipeline's value. The increase in cash is a positive liquidity signal, but it is offset by the negative equity and ongoing burn.

The equity section reveals a pattern of continuous losses and reliance on external capital. The $157M increase in cash between 2024Q1 and 2026Q2, despite cumulative operating losses, indicates significant equity raises that have diluted existing shareholders. The negative equity in 2026Q2 is a red flag, suggesting that the company's liabilities exceed its assets, which may complicate future financing efforts and signal financial distress.

The current ratio has deteriorated sharply, dropping below 1.0 in 2026Q2, which suggests that current liabilities exceed current assets, a concerning liquidity position. Although cash increased to $48.0M, the concurrent rise in liabilities—likely from accrued expenses and debt—has outpaced asset growth. With an operating burn of approximately $10.8M per quarter, the cash runway is roughly 4-5 quarters, but the CRL delay and commercial build-out may accelerate spending, necessitating another capital raise.